Your browser version may not work well with NCBI's Web applications. More information here...
1: PLoS One. 2008 Sep 3;3(9):e3130.Click here to read Click here to read Links

Role of N-terminal amino acids in the potency of anthrax lethal factor.

Laboratory of Bacterial Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.

Anthrax lethal factor (LF) is a Zn(+2)-dependent metalloprotease that cleaves several MAPK kinases and is responsible for the lethality of anthrax lethal toxin (LT). We observed that a recombinant LF (LF-HMA) which differs from wild type LF (LF-A) by the addition of two residues (His-Met) to the native Ala (A) terminus as a result of cloning manipulations has 3-fold lower potency toward cultured cells and experimental animals. We hypothesized that the "N-end rule", which relates the half-life of proteins in cells to the identity of their N-terminal residue, might be operative in the case of LF, so that the N-terminal residue of LF would determine the cytosolic stability and thereby the potency of LF. Mutational studies that replaced the native N-terminal residue of LF with known N-end rule stabilizing or destabilizing residues confirmed that the N-terminal residue plays a significant role in determining the potency of LT for cultured cells and experimental animals. The fact that a commercially-available LF preparation (LF-HMA) that is widely used in basic research studies and for evaluation of vaccines and therapeutics is 3-fold less potent than native LF (LF-A) should be considered when comparing published studies and in the design of future experiments.

PMID: 18769623 [PubMed - indexed for MEDLINE]

PMCID: PMC2518864

Patient Drug Information

  • Anthrax Vaccine (Biothrax® )

    Anthrax is a serious disease that can affect both animals and humans. It is caused by bacteria calledBacillus anthracis. People can get anthrax from contact with infected animals, wool, meat, or hides. In its most common...